

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of Judith Bramel DEELY et al.

International Application No.: PCT/EP2004/13499

International Filing Date: November 25, 2004

For: (+)-(2S,3S)-2-(3-CHLOROPHENYL)-3,5,5-TRIMETHYL-2-MORPHOLINOL FOR TREATING ANXIETY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

☒ Copies of the references are enclosed

☐ Copies of the references were submitted in parent application Serial No. _____.
(37 CFR 1.98(d))

☒ A copy of the International Search Report which issued on International Application No. _____ PCT/EP2004/013499 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

☐ **The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).**

B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:
(1) a final action under § 1.113 or
(2) a notice of allowance under § 1.311,
whichever occurs first.

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).
- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]
- ☐ Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- ☐ The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.
- [X] Please charge any required fees to Deposit Account No.07-1392.
- ☐ A duplicate copy of this paper is attached.

Respectfully Submitted,

/Bonnie L. Deppenbrock/
Bonnie L. Deppenbrock
Attorney of Record
Registration No. 28,209

Date: May 17, 2006
Customer No. 23347
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-1577
Facsimile: (919) 483-7988

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				INT'L FILING NO.		PCT/EP2004/013248	
				INT'L FILING DATE		November 19, 2004	
				APPLICANT		Judith Bramel Deely	
				GROUP			
				EXAMINER			
				ATTORNEY DOCKET NO.		PB60596USw	
U.S. PATENT DOCUMENTS							
Examiner Initials	Serial Number	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	1.	6,342,496	1/29/2002	Jerussi et al.			
	2.	6,337,328	1/8/2002	Fang et al.			
	3.	6,391,875	5/21/2002	Morgan et al.			
	4.	6,274,579	8/14/2001	Morgan et al.			
	5.	2002/052340	5/2/2002	Jerussi et al.			
	6.	2002/052341	5/2/2002	Fang et al.			
	7.	2003/064988	4/3/2003	Morgan et al.			
	8.	2003/032643	2/13/2003	Ascher et al.			
	9.	2003/083330	5/1/2003	Partridge			
	10.	2003/027827	2/6/2003	Broom et al.			
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	11.	WO 01/62257	8/30/2001	PCT			
	12.	WO 00/51546	9/8/2000	PCT			
	13.	WO 99/37305	7/29/1999	PCT			
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
	14.	ASCHER et al., Burpropion: A Review of its Mechanics and Antidepressant Activity, J. Clinical Psychiatry 56 :395-401 (1985)					
	15.	BONDAREV et al., Behavioral and Biochemical Investigations of Bupropion Metabolites, Eur. J. of Pharmacology 474(1) :85-93 (2003).					
	16.	COSTALL et al., Exploration of mice in a black and white test box: validation as a model of anxiety, Pharmacology, biochemistry & Behavior 32(3) :777-785 (1989).					
	17.	ECKHARDT et al., A Structure-Activity Study of the Transport Sites for the Hypothalamic and Striatal Catecholamine Uptake Systems, Molecular Pharmacology 21 :374-379 (1982).					
	18.	FILE, Animal Models for Predicting Clinical Efficacy of Anxiolytic Drugs: Social Behaviour, Neuropsychobiology 13 :55-62 (1985).					
	19.	STAHL et al., A Review of the Neuropharmacology of Bupropion, A Dual Norepinephrine and Dopamine Reuptake Inhibitor, Prim Care Companion J. Clin Psychiatry 6(4) :159-166 (2004).					
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							